Ken White Lab

The goals of this project are to understand the function of soluble isoforms of the FGF23 co-receptor Klotho.

The goal of this proposal is to test novel kidney FGF23-Klotho signaling pathways.

The goal of this proposal is to generate pilot data for integrated, larger proposals in CKD and metabolic bone disease. (White, Allen, Moe co-PI)

The goal of this proposal is to test new hypotheses on the regulation of FGF23 in vivo.

J.M. Hum, E.L. Clinkenbeard, C. Ip, T.A. Cass, M.R. Allen, and K.E. White. The metabolic bone disease associated with the Hyp mutation is independent of osteoblastic HIF1α expression. 2017. Bone Reports; 6:38-43. PMID: 28377980; PMCID: PMC5365303.

E.L. Clinkenbeard, K.R. Stayrook, H.N.Appaiah, M.R. Hanudel, E.G. Farrow, T.A. Cass, L.J. Summers, C.S. Ip, J.M. Hum, J.C. Thomas, M. Ivan, B.R. Richine, R.J. Chan, T.L. Clemens, E. Schipani, Y. Sabbagh, L. Xu, E.F. Srour, M.B. Alvarez, M.A. Kacena, I.B. Salusky, T. Ganz, E. Nemeth and K.E. White. Erythropoietin (EPO) Induces Fibroblast growth factor-23 (FGF23), revealing novel roles for bone and bone marrow in renal failure. 2017. Hematologica, In press. PMID: 28818868; DOI: 10.3324/haematol.2017.167882.

J.C. Fleet, R.A. Replogle, P. Reyes-Fernandez, L. Wang, M. Zhang, E.L. Clinkenbeard, and K.E. White. Gene-by-diet interactions affect serum 1,25 dihydroxyvitamin D levels in male BXD recombinant inbred mice. 2016. Endocrinology, 157(2):470-81. PMID: 26587785; PMCID: PMC4733130.

E.L. Clinkenbeard, T.A. Cass, P. Ni, J.M. Hum, T. Bellido, M.R. Allen, and K.E. White. Conditional deletion of murine Fgf23: Interruption of the normal skeletal responses to phosphate challenge and rescue of genetic hypophosphatemia. 2016. J Bone Mineral Rsch, 31(6):1247-57. PMID: 26792657; PMCID: PMC4891276.

J.M. Hum, L.M. O’Bryan, E.L. Clinkenbeard, R.C. Smith, and K.E. White. A soluble form of αKlotho prevents aortic calcification and disease phenotypes during chronic hyperphosphatemia. 2016. JASN; 28(4):1162-1174. PMID: 27837149; PMCID: PMC5373441.